Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: A phase IV, randomized, open-label, controlled study  by Izurieta, Patricia et al.
I
i
o
P
M
a
b
c
K
d
e
f
a
A
R
R
A
A
K
A
H
P
K
t
C
D
h
g
a
H
h
0Vaccine 33 (2015) 2800–2807
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
mmunogenicity  and  safety  of  an  AS03-adjuvanted  H5N1  pandemic
nﬂuenza  vaccine  in  Korean  adults:  A  phase  IV,  randomized,
pen-label,  controlled  study
atricia  Izurietaa,∗,  Woo  Joo  Kimb, Seong-Heon  Wiec, Jacob  Leed, Jin-Soo  Leee,
amadou  Draméf, David  W.  Vaughnf, Anne  Schuindf
GSK Vaccines, Wavre, Belgium
Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, South
orea
Division of Infectious Diseases, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, South Korea
Division of Infectious Diseases, Department of Internal Medicine, Inha University School of Medicine, Incheon, South Korea
GSK Vaccines, King of Prussia, PA, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 13 February 2015
eceived in revised form 8 April 2015
ccepted 9 April 2015
vailable online 21 April 2015
eywords:
S03
5N1 vaccine
andemic inﬂuenza
orean adults
a  b  s  t  r  a  c  t
Background:  AS03-adjuvanted  H5N1  pandemic  inﬂuenza  vaccines  have  been  assessed  in an  extensive
clinical  development  program  conducted  in  North  America,  Europe,  and  Asia  including  children  from  6
months  of age,  adults,  and  elderly  adults.  We evaluated  AS03-H5N1  in  Korean  adults  18 through  60 years
of age.
Methods:  This  Phase  IV,  randomized,  study  was  conducted  to assess  the immunogenicity,  reacto-
genicity,  and  safety  of two  doses  (3.75  g of hemagglutinin  antigen)  of  A/Indonesia/5/2005  (H5N1)
adjuvanted  with  AS03  given  21  days  apart  in Korean  adults.  Antibody  responses  were  assessed  using
hemagglutination-inhibition  (HI)  assays  against  the  vaccine  strain  and  a  vaccine-heterologous  strain
(A/Vietnam/1194/2004)  21 days  after  the  second  dose.  A control  group  (safety)  received  a licensed  sea-
sonal  inactivated  trivalent  inﬂuenza  vaccine  (TIV).  Reactogenicity  was  assessed  for 7  days  after  each
vaccination,  and  unsolicited  adverse  events  were  assessed  for 182  days  following  vaccination  in  both
study  groups  (NCT01730378).
Results: AS03-H5N1  was  immunogenic  and  elicited  robust  HI antibody  responses  with  seroconversion
rates  of  100%  for  the vaccine  strain  and  69.1%  for the  heterologous  strain  (N =  81). HI antibody  responses
fulﬁlled  the European  licensure  criteria  for immunogenicity  (primary  endpoint).  The  incidence  of local
and systemic  solicited  adverse  events  (reactogenicity)  was  higher  with  AS03-H5N1  than  TIV.  There  was
no apparent  difference  in  the  rate  of  unsolicited  adverse  events  in  the  AS03-H5N1  and  TIV  groups.
Conclusion:  The  results  indicate  that  AS03-H5N1  vaccine  is  immunogenic  with  reactogenicity  and  safety
ﬁndings  that are  consistent  with  the  established  proﬁle  of  AS03-H5N1  vaccine.
ublis©  2015  The  Authors.  PAbbreviations: AEs, adverse events; CBER, US Center for Biologics Evalua-
ion and Research; CHMP, Committee for Medicinal Products for Human Use;
I,  conﬁdence interval; EMA, European Medicines Agency; FDA, US Food and
rug Administration; GMT, geometric mean titer; HA, hemagglutinin antigen; HI,
emagglutination-inhibition; MAEs, medically-attended adverse events; MGI, mean
eometric increase; pIMDs, potentially immune-mediated diseases; SAE, serious
dverse event; SCR, seroconversion rate; SPR, seroprotection rates; WHO, World
ealth Organization.
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The World Health Organization (WHO) reported 667 human
cases of avian-origin H5N1 infection from 2003 to July 2014, of
which 393 were fatal [1]. The unpredictable nature of avian-origin
H5N1 inﬂuenza should not be underestimated, and the develop-
ment of vaccines against inﬂuenza viruses with pandemic-potential
is a public health priority.GSK Vaccines has produced H5N1 vaccines containing the
A/Vietnam or A/Indonesia antigen formulated with the oil-in-
water Adjuvant System, AS03. The AS03-adjuvanted H5N1 vaccines
(AS03-H5N1) are manufactured at sites in Dresden, Germany,
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nd Quebec, Canada, and are licensed in Europe and the US
PrepandrixTM; AdjupanrixTM; PumarixTM; Q-Pan H5N1 inﬂuenza
accine) [2,3]. AS03-H5N1 vaccines have been assessed in large
tudies in North America, Europe, and Asia, including children from
 months of age, adults, and elderly adults [4–10].
Pivotal Phase 3 trials in European and Asian adults showed that
wo doses of AS03-H5N1 (A/Vietnam/1194/2004) vaccine contain-
ng 3.75 g of hemagglutinin antigen (HA) was more immunogenic
han non-adjuvanted vaccines [4,8,11]. Across the clinical devel-
pment program, AS03-H5N1 vaccines have been shown to elicit
trong, durable, cross-clade immune responses [4–8]. Furthermore,
 long-term extension phase of the Asian study conducted in
aiwan, Thailand, Singapore, and Hong Kong, suggested that vac-
inated populations could potentially be protected for up to three
ears after vaccination, which is likely to far exceed the peak of
andemic transmission [12]. The results of the long-term study
howed that AS03-H5N1 vaccine may  be used according to ﬂex-
ble prime–boost vaccination schedules, with strong cross-clade
namnestic antibody responses observed after one dose of AS03-
5N1 heterologous booster vaccine given at 6, 12, or 36 months
fter priming with two doses of AS03-H5N1 vaccine [12].
This Phase IV, open-label study was conducted to assess the
mmunogenicity and safety of a two-dose schedule of AS03-H5N1
A/Indonesia/5/2005) vaccine in Korean adults.
. Methods
.1. Design and objectives
This Phase IV, randomized, open-label study evaluated the
mmunogenicity, reactogenicity, and safety of a two-dose primary
accination series of AS03-H5N1 (A/Indonesia/5/2005) vaccine in
dults. A safety control group received one dose of seasonal inacti-
ated trivalent inﬂuenza vaccine (TIV). The study was multi-center
nd conducted in the Republic of Korea.
The main immunogenicity objective (primary outcome)
as to assess if two doses of AS03-H5N1 vaccine elicited
emagglutination-inhibition (HI)-based immune responses
gainst the vaccine strain (A/Indonesia/5/2005) which fulﬁlled
he European Medicines Agency (EMA) Committee for Medicinal
roducts for Human Use (CHMP) licensure criteria for the approval
f pandemic inﬂuenza vaccines [13]. The main safety objective
secondary outcome) was to evaluate solicited adverse events
AEs) and unsolicited AEs in the AS03-H5N1 group and the TIV
ontrol group.
Men  and women were eligible for inclusion if they were 18
hrough 60 years of age at the ﬁrst vaccination. Subjects were
equired to be in good general health with no acute illness and
ontrolled chronic conditions. Subjects could not have received any
easonal or pandemic inﬂuenza vaccine within six months before
tudy vaccination or during the study period. Women  of child bear-
ng potential were required to use reliable contraception.
All protocols and study documentation were approved by inde-
endent/local ethics committees in accordance with Good Clinical
ractice, the Declaration of Helsinki, and regulatory requirements.
ClinicalTrials.gov NCT01730378). Subjects provided informed
ritten consent.
.2. Vaccines and randomization
The study vaccine was an H5N1 inactivated, split-virion
ecombinant inﬂuenza vaccine manufactured by GSK Vaccines
n Dresden, Germany. Each dose of vaccine contained 3.75 g
A of A/Indonesia/05/2005 adjuvanted with AS03, an oil-in-
ater emulsion based Adjuvant System containing 11.86 mg  of3 (2015) 2800–2807 2801
-tocopherol. The control vaccine was  a licenced TIV for sea-
sonal inﬂuenza (FluarixTM, GSK Vaccines) containing 15 g of
each HA that was recommended by the WHO  for the 2012/13
inﬂuenza season in the Northern Hemisphere: A/Christchurch/
16/10 (H1N1), A/Victoria/361/2011 (H3N2), and B/Hubei-
Wujiagang/158/2009 (Yamagata lineage inﬂuenza B strain).
The lot numbers were AFLSA340A (H5N1), AA03A209C (AS03),
and AFLUA696A (FluarixTM).
Subjects were scheduled to receive two doses 21 days apart
of AS03-H5N1 or one dose of TIV control vaccine, which were
administered open-label in the deltoid muscle. Randomization was
performed by GSK Vaccines (Rixensart, Belgium) using a blocking
scheme developed in SAS® (Cary, NC, USA). Vaccines were allocated
at each study site using an internet-based randomization system.
Subjects were randomized 2:1 to receive AS03-H5N1 or control TIV,
and a minimisation procedure was used to account for center, age
strata (about 1:1 for 18–40 years and 41–60 years), and history of
seasonal inﬂuenza vaccination and/or A(H1N1)pdm09 vaccine in
preceding three seasons.
2.3. Immunogenicity assessments
Blood samples were taken for the evaluation of immune
responses on Day 0, 21, and 42 in the AS03-H5N1 vaccine group
(before and 21 days after each dose), and on Day 0 and 21 in the
TIV group. In the AS03-H5N1 vaccines group, HI assays were per-
formed using an established HI method, modiﬁed for equine rather
than avian erythrocytes [14–16]. In the TIV group, HI assays against
the three vaccine strains were measured using a validated method
as previously described [17]. All serological testing was  performed
at a central GSK Vaccines laboratory.
The primary endpoint was the measurement of HI antibodies
against A/Indonesia/5/2005 at Day 42 (21 days after the second
vaccination) to evaluate whether two  doses AS03-H5N1 vaccine
elicited immune responses that fulﬁlled the CHMP licensure crite-
ria for immunogenicity [13]. Secondary immunogenicity endpoints
were to assess if two doses of vaccine fulﬁlled the US Food and
Drug Administration (FDA) Center for Biologics Evaluation and
Research (CBER) licensure criteria for immunogenicity [18], and
to assess HI antibody responses after one dose of AS03-H5N1
vaccine. Tertiary immunogenicity analyses were the assessment
of Day 42 HI antibody responses against a vaccine-heterologous
strain (A/Vietnam/1194/2004), and vaccine-homologous responses
according to age (18–40 years or 41–60 years), and according to
previous vaccination history (vaccinated or not vaccinated against
seasonal or A(H1N1)pdm09 inﬂuenza during the previous three
seasons). HI immune responses to the three strains in the TIV con-
trol vaccine were also assessed.
HI antibody parameters were Geometric Mean Titre (GMT),
seroconversion rate (SCR; deﬁned as percentage of subjects achiev-
ing an increase in HI titers from <1:10 to ≥1:40 or at least a 4-fold
post-vaccination increase in HI titer from a pre-vaccination titer
≥1:10), seroprotection rate (SPR; percentage of subjects with HI
titers ≥1:40 following vaccination), and Mean Geometric Increase
(MGI; geometric mean of the ratio between post-vaccination and
pre-vaccination reciprocal HI titers). Subjects with HI antibody
titers of ≥1:10 were considered to be seropositive.
2.4. Reactogenicity and safety assessments
The secondary reactogenicity and safety endpoints were
assessed in both study groups.Solicited local and general symptoms were assessed during the
7-day post-vaccination period after each dose. Subjects recorded
the occurrence and severity of solicited events on diary cards.
Local (injection site) symptoms were pain, redness, and swelling,
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nd general symptoms were fatigue, fever, gastrointestinal symp-
oms, headache, joint pain, muscle aches, shivering, sweating.
ever was deﬁned as a temperature of ≥38.0 ◦C (≥100.4 ◦F) by any
oute or method. All solicited local events were considered to be
accine-related, and investigators provided causality assessments
or solicited general events.
Unsolicited AEs were recorded for 21 days after each dose of
S03-H5N1 vaccine and after the single dose of TIV control vac-
ine. Unsolicited AEs were also recorded from Day 0 to Day 84
n the AS03-H5N1 and TIV control groups. Serious adverse events
SAEs), medically-attended adverse events (MAEs) and potential
mmune-mediated diseases (pIMDs) were recorded from Day 0 to
ay 184. Unsolicited events were coded using the Medical Dictio-
ary for Regulatory Activities and investigators provided causality
ssessments for all adverse events.
.5. Analyses
The sample size power calculation was based on a previous
tudy of two doses of AS03-H5N1 vaccine in 155 subjects 18
hrough 60 years of age in which the SPR and SCR was  98.7% and the
GI  was 121.9 [19]. We  calculated that a sample size of 68 evalu-
ble subjects would allow for at least 95% power to demonstrate
he primary endpoint. Allowing for a 20% drop-out or protocol vio-
ation rate, the target population was 84 subjects in the AS03-H5N1
roup.
Immunogenicity data were summarized with 95% Conﬁdence
ntervals (CIs). The CHMP licensure criteria were fulﬁlled if the
oint estimate for SCR was >40%, SPR was >70%, and MGI was >2.5
13]. CBER licensure criteria were fulﬁlled if the lower limits of the
5% CI for SCR was ≥40% and for SPR was ≥70% [18]. Immuno-
enicity was described in the per-protocol immunogenicity cohort
ncluding subjects who met  the eligibility criteria, complied with
he protocol, and for whom data were available at the speciﬁed
valuation time point.
AS03A–H5N1 TIV
Enrolled
N=84 N=47
AS0 3A–H5N1 TIV
Total v acc inated cohort
N=84 N=47
AS0 3A–H5N1 TIV
Per -protocol 
immun ogenicity cohort
N=81 N=40
Administr aon of 
forbidd en vacc ine, n= 1
Non-compli ance with 
vaccinaon schedu le, n= 2
Rand omizaon error, n= 5
Underlying condion 
forbidd en by  protocol, n= 1
Non-compli ance with bloo d 
sam pli ng schedu le, n= 1
Fig. 1. Subjec3 (2015) 2800–2807
Reactogenicity and safety data were tabulated with 95% CIs and
were based on the total vaccinated cohort including all subjects
who received at least one dose of either AS03-H5N1 or TIV.
3. Results
A total of 131 subjects were enrolled, including 84 and 47 in the
AS03-H5N1 vaccine and TIV control groups, respectively (Fig. 1).
The mean age (median; range) in the AS03-H5N1 vaccine group was
39.3 years (40.5 years; 18–59 years) and in the TIV control group
was 40.4 years (41.0 years; 20–58 years). In the AS03-H5N1 and
TIV groups, 72.6% and 72.3% of subjects, respectively, were women.
All subjects were Korean with East Asian heritage. An overview of
the analysis groups and reasons for withdrawal is shown in Fig. 1.
The ﬁrst subject was  enrolled in December 2012 and the last study
contact was  in December 2013.
3.1. Immunogenicity
A summary of the HI antibody responses is shown in Fig. 2.
Pre-vaccination, 4.9% of the AS03-H5N1 group was seropositive
for the vaccine strain (A/Indonesia/5/2005). On Days 21 and 42 in
the AS03-H5N1 group, the vaccine-homologous GMTs were 31.8
and 300.1, respectively. The SPR, SCR, and MGI  at Day 42 ful-
ﬁlled the CHMP thresholds for immunogenicity and the SPR and
SCR fulﬁlled the CBER thresholds for immunogenicity (Fig. 2). At
baseline, 65.4% of the AS03-H5N1 group were seropositive for the
vaccine-heterologous strain (A/Vietnam/1194/2004). The Day 42
GMT against the heterologous strain was  54.2, and the SCR and SPR
were >69.1% (Table 1).
HI responses fulﬁlled the primary endpoint regardless of age.
In both age groups, the Day 42 vaccine-homologous SPR and
SCR were 100% (Table 2). In the subgroup analysis, taking into
account seasonal inﬂuenza vaccination history, the Day 42 vaccine-
homologous SPR and SCR was  100% in subjects with and without
inﬂuenza vaccination (Table 3). Pre-vaccination GMTs were similar
Completed Day 182  safety 
follow -up
AS03A–H5N1 TIV
N=83 N=47
Administr aon of 
forbidd en vacc ine, n= 1
ts ﬂow.
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Fig. 2. Hemagglutination-inhibition antibody responses against the vaccine strain (A/Indonesia/5/2005) based on geometric mean titers (A), seroconversion rates and
seroprotection rates (B), and mean geometric increase (C) after two doses of AS03-H5N1 vaccine (per-protocol immunogenicity cohort). Note: Seroconversion rate deﬁned
as  proportion of subjects with a pre-vaccination HI antibody titer <1:10 and post-vaccination HI antibody titer ≥1:40, or subjects with at least a 4-fold increase in the
post-vaccination HI antibody titer; licensure thresholds deﬁned as a point estimate >40% (CHMP) and a lower limit of 95% CI ≥40% (CBER); Seroprotection rate deﬁned as
proportion of subjects with HI antibody titers ≥1:40; licensure threshold deﬁned as a point estimate >70% (CHMP) and a lower limit of 95% CI ≥70% (CBER); Mean geometric
increase deﬁned as the geometric mean of the within subject ratios of reciprocal HI antibody titers for post-vaccination versus pre-vaccination; CHMP threshold deﬁned as
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valuation and Research; CI, conﬁdence interval.
egardless of seasonal vaccination history, and based on non-
verlapping 95% CIs, the Day 42 GMTs appeared to be lower in
he previously vaccinated (177.1; 95% CI: 130.0, 241.2) compared
ith the not previously vaccinated sub-group (374.8; 95% CI: 315.5,
45.2) (Table 3).
One dose of TIV vaccine was immunogenic. The SCRs were 82.5%,
0.0%, and 65.0% against A/H1N1, A/H3N2, and the inﬂuenza B
train, respectively (Supplemental Table 1).
.2. Safety.2.1. Solicited adverse events
Local and general solicited AEs are summarized in Fig. 3. Pain
as the most frequently reported local symptom, and was reportedmmittee for Medicinal Products for Human Use; CBER, the US  Center for Biologics
at the same rate (88.1%; 74/84) after the ﬁrst and after the second
doses of AS03-H5N1 vaccine. In the AS03-H5N1 group overall by
subject (ﬁrst and second doses combined), the frequency of pain
was 95.2% (80/84), and the rate of Grade 3 pain was  9.5% (8/84).
After the single dose of TIV, the frequency of pain was 68.1% (32/47),
and there were no reports at Grade 3. Other local AEs were reported
by <32.1% and <25.7% of subjects overall in the AS03-H5N1 (two
doses) and TIV control (one dose) groups, respectively.
Muscle aches and fatigue were the most frequently reported
general symptoms in both groups. In the AS03-H5N1 group overall
by subject (ﬁrst and second doses combined), muscle aches and
fatigue were reported by 73.8% (62/84) and 64.3% (54/84) sub-
jects, respectively. After one dose of TIV, muscle aches and fatigue
were reported by 27.7% (13/47) and 29.8% (14/47) of subjects,
2804 P. Izurieta et al. / Vaccine 33 (2015) 2800–2807
Table 1
Hemagglutination-inhibition antibody responses against a vaccine-heterologous
strain with AS03-H5N1 vaccine (per-protocol immunogenicity cohort).
Heterologous strain
(A/Vietnam/1194/2004)
N = 81
Seropositive at day 0, % (95% CI) 65.4 (54.0, 75.7)
GMT, value (95% CI) Day 0 9.3 (8.2, 10.5)
Day 21 22.5 (19.4, 26.0)
Day 42 54.2 (48.1, 61.1)
SCR, % (95% CI) Day 21 17.3 (9.8, 27.3)
Day 42 69.1 (57.9, 78.9)
SPR, % (95% CI) Day 0 2.5 (0.3, 8.6)
Day 21 24.7 (15.8, 35.5)
Day 42 82.7 (72.7, 90.2)
MGI, value (95% CI) Day 21 2.4 (2.1, 2.8)
Day 42 5.8 (5.0, 6.8)
Seropositive deﬁned as titer ≥1:10; SCR, seroconversion rate deﬁned as propor-
tion  of subjects with a pre-vaccination HI antibody titer <1:10 and post-vaccination
HI  antibody titer ≥1:40, or subjects with at least a 4-fold increase in the post-
vaccination HI antibody titer; SPR, seroprotection rate deﬁned as proportion of
subjects with HI antibody titers ≥1:40; MGI, mean geometric increase deﬁned as the
geometric mean of the within subject ratios of reciprocal HI antibody titers for post-
vaccination versus pre-vaccination; HI, hemagglutination-inhibition; CI, conﬁdence
interval; GMT, geometric mean titer.
Table 2
Hemagglutination-inhibition antibody responses against the vaccine strain
(A/Indonesia/5/2005) by age group with AS03-H5N1 vaccine (per-protocol immuno-
genicity cohort).
Age group
18–40 years
N  = 40
41–60 years
N  = 41
Seropositive at day 0, % (95% CI) 5.0 (0.6, 16.9) 4.9 (0.6, 16.5)
GMT, value (95% CI) Day 0 5.2 (4.9, 5.4) 5.2 (4.9, 5.4)
Day 21 36.6 (26.9, 49.8) 27.8 (21.6, 35.8)
Day 42 298.6 (235.0, 379.4) 301.6 (236.8,
384.2)
SCR, % (95% CI) Day 21 47.5 (31.5, 63.9) 43.9 (28.5, 60.3)
Day 42 100 (91.2, 100) 100 (91.4, 100)
SPR, % (95% CI) Day 0 0.0 (0.0, 8.8) 0.0 (0.0, 8.6)
Day 21 47.5 (31.5, 63.9) 43.9 (28.5, 60.3)
Day 42 100 (91.2, 100) 100 (91.4, 100)
MGI, value (95% CI) Day 21 7.1 (5.3, 9.5) 5.4 (4.2, 6.9)
Day 42 57.7 (45.2, 73.6) 58.3 (44.9, 75.8)
Seropositive deﬁned as titer ≥1:10; SCR, seroconversion rate deﬁned as propor-
tion  of subjects with a pre-vaccination HI antibody titer <1:10 and post-vaccination
HI  antibody titer ≥1:40, or subjects with at least a 4-fold increase in the post-
vaccination HI antibody titer; SPR, seroprotection rate deﬁned as proportion of
subjects with HI antibody titers ≥1:40; MGI, mean geometric increase deﬁned as
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Table 3
Hemagglutination-inhibition antibody responses against the vaccine strain
(A/Indonesia/5/2005) by previous inﬂuenza vaccination history with AS03-H5N1
vaccine (per-protocol immunogenicity cohort).
No previous
vaccination†
N = 57
Previous
vaccination†
N = 24
Seropositive at day 0, % (95% CI) 1.8 (0.0, 9.4) 12.5 (2.7, 32.4)
GMT, value (95% CI) Day 0 5.1 (4.9, 5.2) 5.5 (4.9, 6.0)
Day 21 35.6 (28.3, 44.8) 24.4 (16.7, 35.8)
Day  42 374.8 (315.5, 445.2) 177.1 (130.0, 241.2)
SCR, % (95% CI) Day 21 50.9 (37.3, 64.4) 33.3 (15.6, 55.3)
Day  42 100 (93.7, 100) 100 (85.8, 100)
SPR, % (95% CI) Day 0 0.0 (0.0, 6.3) 0.0 (0.0, 14.2)
Day 21 50.9 (37.3, 64.4) 33.3 (15.6, 55.3)
Day  42 100 (93.7, 100) 100 (85.8, 100)
MGI, value (95% CI) Day 21 7.0 (5.6, 8.8) 4.5 (3.1, 6.4)
Day 42 74.1 (62.3, 88.0) 32.5 (23.1, 45.7)
Seropositive deﬁned as titer ≥1:10; SCR, seroconversion rate deﬁned as propor-
tion  of subjects with a pre-vaccination HI antibody titer <1:10 and post-vaccination
HI  antibody titer ≥1:40, or subjects with at least a 4-fold increase in the post-
vaccination HI antibody titer; SPR, seroprotection rate deﬁned as proportion of
subjects with HI antibody titers ≥1:40; MGI, mean geometric increase deﬁned as the
geometric mean of the within subject ratios of reciprocal HI antibody titers for post-
vaccination versus pre-vaccination; HI,  hemagglutination-inhibition; CI, conﬁdencehe geometric mean of the within subject ratios of reciprocal HI antibody titers
or  post-vaccination versus pre-vaccination; HI, Hemagglutination-inhibition; CI,
onﬁdence interval; GMT, geometric mean titer.
espectively. There was no increase in the incidence of general
ymptoms after the ﬁrst and second doses of AS03-H5N1 vaccine.
.2.2. Unsolicited adverse events
The rate of unsolicited AEs during the 21 day post-vaccination
eriod(s) was 33.3% (95% CI: 23.4, 44.5) 28/84 subjects in the AS03-
5N1 group (ﬁrst and second doses combined) and 19.1% (95% CI:
.1, 33.3) 9/47 subjects in the TIV group (single dose), which was
ost frequently injection site pruritus or nasopharyngitis (both
.8%) in the AS03-H5N1 group, and pharyngitis, nasopharyngitis,
yspepsia, or rhinorrhoea (each 4.3%) in the TIV group. During the
1-day post-vaccination period(s), a Grade 3 unsolicited AE was
eported by one subject in the AS03-H5N1 group (gastroenteritis)
nd one subject in the TIV group (nasopharyngitis). During the 21
ay post-vaccination period(s), 14.3% (95% CI: 7.6, 23.6) 12/84 and
.3% (95% CI: 0.5, 14.5) 2/47 subjects of the unsolicited AEs in theinterval; GMT, geometric mean titer.
† Did (yes) or did not (no) receive seasonal inﬂuenza vaccination and/or
A(H1N1)pdm09 vaccine in preceding three seasons.
AS03-H5N1 and TIV groups, respectively, were considered by the
investigator to be vaccine-related. The rate of unsolicited AEs from
Day 0 to 84 was  34.5% (95% CI: 24.5, 45.7) 29/84 subjects in the
AS03-H5N1 group and 25.5% (95% CI: 13.9, 40.3) 12/47 subjects in
the TIV control group.
From Day 0 to 182, the rate of MAEs was 19.0% (95% CI: 11.3,
29.1) 16/84 subjects in the AS03-H5N1A group and 19.1% (95% CI:
9.1, 33.3) 9/47 subjects in the TIV group. During the study period,
one subject reported 3 SAEs in the AS03-H5N1 group (appendicitis,
endometriosis and right ovarian cysts), which were not considered
to be vaccine-related. There were no SAEs in the TIV group. There
were no pIMDs reported during the study. No subject discontinued
due to an AE.
4. Discussion
This Phase IV open-label study in Korean adults showed that
a two-dose schedule of 3.75 g HA of H5N1 vaccine formu-
lated with AS03 (AS03-H5N1) elicited HI antibody responses
that fulﬁlled the CHMP and CBER licensure criteria for immuno-
genicity. The AS03-H5N1 vaccine was  strongly immunogenic
against the vaccine strain (A/Indonesia/5/2005) and a heterolo-
gous strain (A/Vietnam/1194/2004). These results are consistent
with previous studies which show strong immune responses
with AS03-adjuvanted H5N1 vaccines, despite the relatively weak
immunogenicity of avian H5N1 in humans [8,11,20,21]. The reac-
togenicity and safety proﬁle of the AS03-H5N1 vaccine was also
consistent with that reported previously, including North Ameri-
can, European, and Asian populations [4,6,7,22].
The provision of adequate vaccine coverage in the event of the
emergence and global spread of a highly pathogenic H5N1 virus
represents a major manufacturing and logistical challenge. A key
strategy for pandemic preparedness is the formulation of vaccines
with an adjuvant to decrease the amount of antigen needed per
dose (‘antigen sparing’), which will increase the number of doses
available early in the response; the batches of vaccine and adju-
vant can be stockpiled to be deployed in a pre-pandemic setting
[23–26]. The stockpiled vaccines may  be subtype-matched but not
strain-matched to the emerging virus, and can be used to prime
the population in advance of the manufacture of a booster vaccine
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Fig. 3. Solicited local adverse events (A) and general adverse events (B) during the 7-day post-vaccination period in the total vaccinated cohort. Note: †  Overall AEs for dose
1  and 2; Grade 3 events deﬁned as severe events which prevent daily activities; Grade 3 redness and swelling deﬁned as diameter >100 mm;  Grade 3 fever deﬁned as a
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Demperature >39 ◦C. CI, conﬁdence interval; TIV, inactivated trivalent inﬂuenza vacc
gainst the pandemic strain [23–26]. The successful implementa-
ion of a pandemic vaccination strategy using stockpiled vaccine
ill depend upon the availability of vaccines that provide some
egree of cross-reactive immunogenicity, and therefore can be used
ccording to various prime–boost strategies.
Previous studies have shown that two doses of AS03-H5N1 vac-
ine containing 3.75 g of HA are immunogenic against the vaccine
train and that up to 36 months after initial vaccination, a further
ingle dose of booster AS03-H5N1 vaccine against a drifted strain
licits strong immune responses against the priming and drifted
trains [12,26]. We  now show that AS03-H5N1 vaccine provides
obust HI antibody responses against vaccine homologous and het-
rologous strains in Korean adults. Sub-group analyses showed
hat post-vaccination HI GMTs were lower in subjects who  had
eceived one or more seasonal inﬂuenza vaccinations within the
revious 3 seasons compared with those who had not (177.1 versus
74.8, respectively). This ﬁnding is consistent with previous stud-
es which reported lower immune responses following pandemic
nﬂuenza vaccination in subjects who had previously received sea-
onal inﬂuenza vaccine compared with those who had not [27–30].
espite the lower immune response in subjects having previouslyreceived seasonal ﬂu vaccines in our study, SCRs and SPRs were
100% against the vaccine strain regardless of vaccination history,
and immunogenicity met  the regulatory acceptance criteria.
We observed baseline seropositive (HI titer ≥1:10) rates of 4.9%
for A/Indonesia and 65.4% for A/Vietnam, although GMTs were low,
and most subjects who  were seroposotive at baseline had titers
close to the assay cut-off. Exposure to H5N1 virus is unlikely and
is reported to have a low impact on sero-epidemiology of H5N1
[31,32]. In South Korea, for example, during the 2003/04 outbreak of
inﬂuenza in ducks and chickens (A/goose/Guangdong/1/96 lineage;
clade 2.5), among a sample of 2,512 bird cullers, there were only 9
conﬁrmed/suspected cases of the prevalent H5N1 virus, suggesting
that poultry-to-human transmission is low even among high-risk
workers [31]. The relatively high baseline seropositivity rate for
A/Vietnam suggests that cross-reacting antibodies with a related or
unrelated antigen may  lead to some H5N1 antibody cross-reactivity
in the lower range.The reactogenicity and safety proﬁle of AS03-H5N1 vaccine in
our study was consistent with that reported previously [4,6,7,22].
After the ﬁrst dose of AS03-H5N1 vaccine, we observed a higher rate
of injection site reactions and systemic reactions compared with
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ne dose of TIV, and this ﬁnding is consistent with previous stud-
es showing that adjuvanted vaccine is typically more reactogenic
han non-adjuvanted vaccine. The short- and longer-term AE pro-
les were similar between the AS03-H5N1 and TIV control groups,
ith 19% of each group reporting a medically-attended event up
o 182 days after vaccination. One subject reported an SAE (AS03-
5N1 group) which was not considered to be vaccine-related, and
o subject withdrew from the study due to an AE.
Epidemiological data currently available to GSK suggest an
ncreased risk of narcolepsy following vaccination with the H1N1
accine PandemrixTM [33–37]. No cases of narcolepsy were detected
n this study of an H5N1 vaccine.
In conclusion, AS03-H5N1 vaccine was immunogenic in Korean
dults up to 60 years of age with HI antibody responses that fulﬁlled
HMP licensure criteria for immunogenicity. The reactogenicity
nd safety proﬁle of AS03-H5N1 vaccine was consistent with that
reviously reported throughout the extensive clinical development
rogram of this vaccine.
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